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ABSTRACT
Elevated blood pressure (BP), or hypertension (HTN), can cause a cascade of detrimental effects to the
body. It is associated with increased risk of stroke, angina, myocardial infarction, heart failure, peripheral
artery disease, end-stage renal disease, and abdominal aortic aneurysms (Whelton et al., 2018). HTN is
also a major risk factor for the development of cardiovascular disease (CVD), which is the United States’
(U.S.) leading cause of death in men and women (U.S. Preventive Services Task Force [USPSTF], 2020).
The PICOT question for this project was: does an eight-week (T) structured walking program utilizing a
smartwatch for step counts and education (I) reduce BP and increase the number of minutes of weekly
moderate-intensity walking (O) in adults aged 18 years or older with essential hypertension (P) compared
to baseline (C)? Thirteen participants from a large family practice office in Northwest Indiana completed
the eight-week within-group project. Baseline BPs were measured, minutes per week of moderateintensity walking at baseline were recorded, and education about HTN was given verbally and visually
using handouts. The participants were instructed to walk at a moderate intensity for at least 90 minutes
per week during weeks one through four, at least 120 minutes during weeks five and six, and at least 150
minutes during weeks seven and eight. At four weeks, a follow-up visit served to reinforce education and
adherence to the program. At the week eight visit, participant logs of minutes per week of moderateintensity walking were collected, and BP was measured. Wilcoxon Signed Rank Tests were used to
analyze systolic BP (SBP), diastolic BP (DBP), and minutes per week of moderate-intensity walking
(MIW). Statistically significant differences were found in SBP (p = .007), DBP (p = .021), and minutes per
week of MIW (p = .005). These findings indicate that a structured walking program can help people with
HTN reduce their BP by walking at a moderate intensity for 90 to 150 minutes per week.
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CHAPTER 1
INTRODUCTION
Background
Elevated blood pressure, or hypertension, can cause a cascade of detrimental effects to
the body. It is associated with increased risk of stroke, angina, myocardial infarction, heart
failure, peripheral artery disease, end-stage renal disease, and abdominal aortic aneurysms
(Whelton et al., 2018). Hypertension is also a major risk factor for the development of
cardiovascular disease (CVD), which is the United States’ (U.S.) leading cause of death in men
and women (U.S. Preventive Services Task Force [USPSTF], 2020). Hypertension was
responsible for more CVD deaths than any of the other modifiable risk factors for CVD (Whelton
et al., 2018). Modifiable risk factors for CVD that are commonly found in people with
hypertension include physical inactivity and/or low fitness, current cigarette smoking or exposure
to secondhand smoking, diabetes mellitus, dyslipidemia and/or hypercholesterolemia, overweight
and/or obesity, and unhealthy diet (Whelton et al., 2018).
Hypertension often has no symptoms, therefore necessitating blood pressure (BP)
monitoring. BP is recorded using two numbers, the systolic blood pressure (SBP) and the
diastolic blood pressure (DBP). SBP is the pressure that is exerted on the arteries during systole,
or when the heart contracts (beats). DBP is the pressure exerted on the arteries when the heart
relaxes between beats. Korotkoff sounds are the five sounds heard during auscultation when
measuring blood pressure using a stethoscope and a blood pressure cuff, or
sphygmomanometer. The SBP is the first Korotkoff sound, and the DBP is the fifth Korotkoff
sound when a manual BP is being performed (Whelton et al., 2018).
New guidelines that were published in 2018 lowered the threshold for diagnosing
elevated BP and hypertension (see Table 1.1). Evidence demonstrated there were increased
risks of CVD events with SBP and DBP values that were below previous guidelines. The term
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‘elevated blood pressure’ is defined as a SBP that is between 120 and 129 mmHg and a DBP
that is less than 80 mmHg. Stage 1 hypertension is defined as a SBP between 130 and 139
mmHg or a DBP between 80 and 89 mmHg. Stage 2 hypertension is defined as a SBP greater
than or equal to 140 mmHg or a DBP greater than or equal to 90 mmHg (Whelton et al., 2018).

Table 1.1
New Guidelines for Blood Pressure Categories
Systolic

Diastolic

Normal BP

<120 mmHg

and

<80 mmHg

Elevated BP

120-129 mmHg

and

<80 mmHg

Stage 1 HTN

130-139 mmHg

or

80-89 mmHg

Stage 2 HTN

≥ 140 mmHg

or

≥90 mmHg

Note. BP = blood pressure; HTN = hypertension.

Hypertension is divided into two categories based upon the identified etiology. Primary
hypertension, or essential hypertension, is hypertension that has no identifiable cause. The
historical features that have shown to correlate with primary hypertension include gradual
increases in BP, family history of hypertension, and lifestyle factors that favor higher BP which
include decreased physical activity, weight gain, high-sodium diet, job change requiring
increased travel, and excessive consumption of alcohol. Often, primary hypertension is
differentiated from secondary causes of hypertension on the basis of these factors (Whelton et
al., 2018). Secondary hypertension is hypertension that is caused by a medical condition, such
as primary aldosteronism, renovascular disease, obstructive sleep apnea, Cushing’s syndrome,
or it can be drug or alcohol induced (Whelton et al., 2018). Regardless of the etiology, over time,
the heart wall thickens to decrease oxygen demand and stress on itself due to the presence of
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hypertension, and this can lead to left ventricular hypertrophy and eventual heart failure.
Engaging in exercise leads to beneficial structure changes of the heart, but the structure
changes found in hypertension are pathological. These changes are associated with myocyte
hypertrophy and fibrosis (Hegde & Solomon, 2015).
Effective control of stage 1 hypertension has been shown to reduce cardiovascular
disease by 10% (Lee et al., 2021; Whelton et al., 2018). Reducing any stage of hypertension can
also prevent kidney damage and decrease the likelihood of morbidity from other health problems,
such as peripheral artery disease, coronary artery disease, and stroke. Pharmacologic ways to
reduce blood pressure (BP) can have side effects and potential noncompliance problems in
those with hypertension, which makes nonpharmacologic interventions essential in helping to
control hypertension (Lee et al, 2021). Some people with hypertension are able to avoid needing
medications by using nonpharmacological interventions to reduce their BP. One of the ways that
hypertension can be reduced is with regular physical activity (Lee et al., 2021; Whelton et al.,
2018; World Health Organization [WHO], 2021).
Data Supporting Need for the Project
Global and National Data
Hypertension is a major cause of premature death worldwide (WHO, 2021). It is
estimated that 1.13 billion people have hypertension, and it is responsible for about nine million
deaths worldwide every year (Lee et al., 2021). Approximately 46% of Americans are classified
as having hypertension under the new guidelines (Dempsey et al., 2018). The definition of
controlled BP is a SBP less than 120 mmHg and a DBP less than 80 mmHg. In the U.S.,
approximately three in four adults with hypertension do not have it under control (Centers for
Disease Control and Prevention [CDC], 2020a). Hypertension was responsible for or contributed
to the death of greater than 494,873 people in 2018 in the U.S. (CDC, 2020a). It is estimated that
hypertension costs the U.S. $131 billon each year (CDC, 2020a). It is often referred to as a
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“silent killer” because hypertension does not usually have symptoms, making screening essential
to identify individuals at risk.
There are situations when only lifestyle modifications are appropriate for treatment of
hypertension. The Atherosclerotic Cardiovascular Disease (ASCVD) risk score is used to
estimate the person’s risk of cardiovascular disease in 10 years using a person’s age, sex, race,
SBP, DBP, total cholesterol, HDL cholesterol, LDL cholesterol, history of diabetes, smoking
status, use of hypertension medication, use of a statin, and use of aspirin (American College of
Cardiology [ACC], n.d.). A value less than 5% is considered low-risk, 5% to 7.4% is borderline
risk, 7.5% to 19.9% is intermediate risk, and equal to or greater than 20% is considered high risk
of developing cardiovascular disease within 10 years (ACC, n.d.). Twelve percent of U.S. adults
have elevated BP, and 9% of U.S. adults have stage 1 hypertension but have an ASCVD risk
score less than 10%. These two situations meet criteria for lifestyle modifications only. In the
U.S., this is around 53 million people (Barone Gibbs et al., 2021).
Physical inactivity is one of the common CVD modifiable risk factors found in people who
have hypertension. It contributes to the major underlying causes of hypertension (Whelton et al.,
2018). Physical inactivity is defined as a self-reported lack of engaging in physical activity during
the past month. Across the U.S., there were greater than 15% of adults who considered
themselves physically inactive in 2020, which puts them at greater risk of hypertension (CDC,
2021b).
Lifetime Risk
The lifetime risk is a measure of risk that an event will happen in a person’s lifetime. The
lifetime risk of hypertension has been studied extensively. For adults who did not have
hypertension at the age of 45 years, 93% of African Americans, 92% of Hispanics, 86% of
whites, and 84% of Chinese adults had a 40-year risk of developing hypertension (Whelton et al.,
2018). Ninety percent of adults without hypertension at the ages of 55 or 65 years developed
hypertension at some point in their lives in the Framingham Heart Study, which involved 6,000
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participants over a 24-year study on the development of cardiovascular disease (Harvard
University Press, 2021; Whelton et al., 2018). Important to note is that the cutoff for hypertension
was 140/90 mmHg at the time of this study, which would mean there likely was a much higher
percentage of adults who developed hypertension under the new cutoff guidelines of 130/80
mmHg (Whelton et al., 2018).
State and City Data
Over a third of Indiana Hoosiers were diagnosed with hypertension in 2017 (Indiana
Department of Health, 2021). In 2019, the mortality rate of Hoosiers related to hypertension was
10.4% (CDC, 2021a). In the city where this project was implemented, Valparaiso, the prevalence
of hypertension in those 18 years or older ranged from 18.7% to 35.4% (CDC, 2017). Data for
the city was not available, but the percentage of Indiana Hoosiers that reported being physically
inactive in 2020 was 28.3% (CDC, 2021b). These statistics demonstrate the relationship that
exists between being physically inactive and having hypertension.
Clinical Agency Data
As of August 2021, there were 1,979 patients out of 15,260 total patients seen by five
providers at the project site that had the ICD-10 code I10 Essential (primary) hypertension in
their electronic medical record (EMR) (D. Smith, personal communication, August 5, 2021). If the
patient has their hypertension under control using pharmacological therapy, the provider sees
these patients every six months. If patients with hypertension require adjustment to their
pharmacological therapy, the provider sees these patients every one month until their BP is
under control. However, if the patient had a SBP greater than 140 mmHg or DBP greater than 90
mmHg, the patient would be seen within one month. If a patient had a SBP much higher than
140 mmHg or much higher than 90 mmHg, they would be seen within a few days for their safety
(Dr. E. Lin, personal communication, June 22, 2021).
Purpose of the Evidence-Based Practice Project
Purpose Statement and PICOT Question
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The purpose of this EBP project is to reduce BP in people who have elevated BP or
hypertension through increased physical activity time and decreased sedentary time. The
prevalence of hypertension and its detrimental effects to the body drove the desire to conduct a
project to empower patients at no cost to improve their health outcomes. A modifiable risk factor
related to this project, moderate-intensity physical activity, is feasible and readily available to
almost every patient with hypertension. Specifically, this project will address the following PICOT
question: does an 8-week (T) structured walking program utilizing a smartwatch for step counts
and education (I) reduce BP and increase the number of minutes of weekly moderate-intensity
walking (O) in adults aged 18 years or older with essential hypertension (P) compared to
baseline (C)?
EBP Project Description
This EBP project will be implemented in a large family practice office in Valparaiso, IN.
The project manager will be at the project site during the last week of August and first week and
a half of September 2021. When a patient with the ICD-10 code I10 essential (primary)
hypertension, regardless of BP control, is present in the office for a visit, the project manager will
speak with the patient at the conclusion of their visit. The project manager will briefly explain the
project and determine whether the patient is interested in participating in the project. If the patient
decides to participate, baseline BP and other demographic information will be obtained, and
enrollment in the program will begin. The intervention, which is based upon current evidence, will
include an eight-week walking program that requires patients to walk at a moderate intensity for
at least 90 minutes per week for the first two weeks, at least 120 minutes per week for the third
and fourth week, and at least 150 minutes per week for weeks five through eight. See Appendix
A for the Minutes Per Week of Moderate-Intensity Walking Log Sheet that participants will be
required to fill out. Education on the first day (baseline day; see Appendix B) will be provided
regarding the pathophysiology of hypertension, the consequences of hypertension, the important
effects of physical activity on hypertension, and how to take their BP at home. The participants
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will be instructed to download the mobile application, Pedometer & Step Counter (Version 2.0.0)
[Mobile app] on their iPhone, or Step Tracker – Pedometer Free & Calorie Tracker (Version
1.2.1) on their Android phone (see figures C1 and C2 in Appendix C). They will be asked to
record their step counts at the end of every day on a log sheet provided to them (‘Daily Steps
and Weekly Blood Pressure Log Sheet’; see Appendix D). As is standard of care at the project
site, the participants will be asked to measure their BP at home once a week and record it on the
Daily Steps and Weekly Blood Pressure Log Sheet. If the patient does not own an at-home BP
monitor, they will be instructed to get a weekly BP measurement at a convenient location such as
CVS, Meijer, Walgreens, YMCA, or Walmart. The expected outcome of this project will be
reduced BP and increased number of minutes of physical activity. It is anticipated that these
outcomes will result in a modest reduction in SBP, slight reduction in DBP, and an increase of
physical activity time in minutes per week that meets or exceeds the American College of
Cardiology and American Heart Association (ACC/AHA) recommendations.
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CHAPTER 2
EBP MODEL AND REVIEW OF LITERATURE
Evidence-based Practice Model
This section provides an overview of the EBP model that was used to guide this project,
the extensive literature search that was performed, the quality appraisal tools used to appraise
the articles chosen for synthesis, and the critical synthesis of the literature.
Overview of EBP Model
The Johns Hopkins Nursing Evidence-Based Practice (JHNEBP) model was chosen to
guide this evidence-based practice (EBP) project (JHNEBP, 2022). This model was chosen to
guide this EBP project because it is easy to follow, has clearly defined steps, and is a powerful
tool to integrate the best practices into clinical care. The steps are organized into three basic
stages in the JHNEBP model: practice question, evidence, and translation, or PET. The ‘P’ stage
involves seven steps that are recruiting the interprofessional team, determining responsibility for
project leadership, scheduling team meetings, clarifying and describing the problem, developing
and refining the EBP question, determining the need for an EBP project, and identifying key
stakeholders. The ‘E’ stage involves five steps that are conducting an internal and external
search for the evidence, appraising the level and quality of each piece of evidence, summarizing
the individual evidence, synthesizing the findings, and developing the best evidence
recommendations. The ‘T’ stage involves eight steps that are identifying practice setting-specific
recommendations, creating an action plan, securing support and resources to implement the
action plan, implementing the action plan, evaluating the outcomes to determine if improvements
have been made, reporting the results to the key stakeholders, identifying the next steps, and
finally disseminating the findings. Permission has been granted to use the JHNEBP model; see
Appendix E for documentation.
Literature Search
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Sources Examined for Relevant Evidence
A research librarian assisted the project manager to perform an extensive literature
search to find the most current evidence regarding nonpharmacological interventions to reduce
BP in hypertensive patients. Databases that were searched included Turning Research Into
Practice (TRIP), Joanna Briggs Institute (JBI), Cochrane Library, Cumulative Index to Nursing
and Allied Health Literature (CINAHL), Medline with Full Text via EBSCO, PubMed, and
ProQuest/Nursing and Allied Health. See Figure 2.1 for the PRISMA flow chart for the literature
search. Exclusion criteria in all databases was research that does not include a walking
intervention based on fit and feasibility for the clinical population and the PICOT question.
Keywords for TRIP were “hypertension” AND “lifestyle modification”. Limiters included
from 2016, guidelines, and USA. Two hundred and eighty-eight results were generated. Most
were not applicable to this project. After careful review, two guidelines and one systematic review
were utilized in the development of this project (Barnason et al., 2017; Barone Gibbs et al., 2021;
Whelton et al., 2018).
For JBI, the keywords that were used included “hypertension” AND “lifestyle”. The limiters
were 2016 to 2021, full text, recommended practices, best practice information sheets, evidence
summaries, recommended practices, and systematic reviews. Five results were generated in
which none were kept. The only relevant result did not include physical activity as an intervention
for hypertension, which is a widely, well-known nonpharmacological intervention.
The keywords used for Cochrane included “hypertension” AND “lifestyle” and limiters
included 2016 to 2021, Cochrane Reviews, and search word variations. Twenty-two results were
generated, and one was kept (Lee et al., 2021). There were three other relevant systematic
reviews for hypertension, however, they addressed diet and sodium restriction, and the project
site felt that an exercise-based intervention would be more appropriate for their patient
population.
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Keywords that were used for CINAHL included “hypertension OR blood pressure” (MW
Word in Subject Heading), “life style change*” OR “lifestyle change*” OR “lifestyle modification”
OR “lifestyle intervention” (AB Abstract). Limiters included Scholarly (Peer Reviewed), the years
2016 to 2021, English language, and age groups 19-44 years and 45-64 years. One hundred
and eleven results were generated. Articles that were fully reviewed were eliminated for various
reasons including a multicomponent intervention was used, not being applicable to this EBP
project, and the intervention would not be feasible for this project. One systematic review and
meta-analysis was deemed eligible for synthesis (Lee & Chae, 2020).
The keywords used for Medline with Full text via EBSCO were “hypertension” OR “blood
pressure” (MJ Word in Major Subject Heading) AND “life style change*” OR “lifestyle change*”
OR “lifestyle modification” OR “lifestyle intervention” (AB Abstract). Limiters included 2016 to
2021, English language, ages: Adult: 19-44 years and Middle age: 45-64 years, and Scholarly
(Peer Reviewed) Journals. One hundred and fifty-one results were generated, and one was kept
(Perl et al., 2016). Reasons for exclusion include using a multicomponent intervention, not being
applicable to this EBP project, and the intervention not being feasible for this project.
PubMed keywords were “hypertension” (MeSH Major Topic) AND “life style” (MeSH Major
Topic). Limiters included 2016 to 2021, English language, Books and Documents, Clinical trial,
meta-analysis, randomized controlled trial, review, and systematic review. Sixty-seven results
were generated, and one was kept (Dempsey et al., 2018). The reason for the exclusions was
not being applicable to this project.
The keywords for ProQuest/Nursing and Allied Health were Exact(“hypertension”) AND
“lifestyle modification*”. The limiters included 2016 to 2021, age group: Adult 19-44 years and
Middle ages: 45-64 years, English language, peer reviewed, and scholarly journals. One hundred
and twelve results were generated, and none were kept. Reasons for exclusion included not
being applicable to this project, multicomponent intervention, and an intervention that is not
feasible for this project.
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The systematic review by Lee et al. (2021) was citation chased for relevant RCTs.
Seventy-three RCTs were used in the systematic review, but only 18 were reviewed because
they fell within the date range 2016 to 2021 that was used consistently throughout the literature
search. Three RCTs were eligible for synthesis (Baross et al., 2017; Chiang et al., 2019;
Gradidge & Golele, 2018). Reasons for exclusion for other RCTs were a search using the DOI or
other citation information did not return any results, inability to retrieve the article in English,
multicomponent interventions, and some articles included patients that required an intervention
to be restricted due to a health condition.

Figure 2.1
PRISMA Flow Chart of Literature Search
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Levels of Evidence
The Melnyk & Fineout-Overholt’s levels of evidence hierarchy was used to level the
evidence for this project (2015). This hierarchy is clearly depicted on a pyramid making it easy to
use, and it includes multiple examples of evidence types for each level. There are seven different
levels of evidence in this hierarchy, with level I being the highest level of evidence, which
includes systematic reviews of RCTs and evidence-based clinical practice guidelines that are
based on systematic reviews of RCTs. Level II includes evidence from at least one well-designed
RCT. Level III includes evidence from well-designed controlled trials without randomization
(quasi-experimental). Level IV has evidence from well-designed case-control and cohort studies,
and Level V includes evidence from systematic reviews of descriptive and qualitative studies.
Level VI includes evidence from a single, descriptive or quality study. Level VII is the lowest level
and includes evidence from the opinions of authorities and/or reports of expert committees. As
shown in Table 2.1, there were six level I evidence articles and four level II articles used for this
project.
Analysis and Appraisal of Relevant Evidence
Three different instruments were used to appraise the quality of the evidence used for
this project. The Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument
was used to appraise the two clinical practice guidelines (CPGs), and the two Critical Appraisal
Skills Programme (CASP) checklists was used to appraise the respective systematic reviews
and RCTs. See Table 2.1 for a brief overview and see Appendix F for the Evidence Table that
summarizes the evidence.
Clinical Practice Guidelines
For the two CPGs chosen for this project, the AGREE II instrument (see Appendix G) was
used to evaluate their quality. This instrument has been widely used for CPGs because of its
validity and reliability. The instrument allows the researcher to score each of the 23 items in the
six quality domains on a 7-point Likert scale. A score of seven is the highest score for each item;
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it is indicative of the appraiser “strongly agreeing” with the item in question. A score of one is the
lowest and indicates “strongly disagree”. The appraiser can then develop an overall assessment
of the quality of the CPG and whether the appraiser would recommend it for use (Melnyk &
Fineout-Overholt, 2015). Use of this tool is granted if the citation is provided (Brouwers et al.,
2010).
Systematic Reviews
There were four systematic reviews with one of them also being a meta-analysis. The
CASP checklist specific for systematic reviews (see Appendix H) was used to measure the
quality of these four articles (CASP, 2021a). The CASP checklist has a 28-year history of
focusing on critically appraising evidence-based practice and is widely used around the world to
help healthcare professionals make decisions based on research (Critical Appraisal Skills
Programme (CASP), 2021c).
Randomized Controlled Trials
The four RCTs used for this project were evaluated for quality by the CASP Randomized
Controlled Trial Checklist (CASP, 2021b). This checklist contains ten questions to guide the
reader in evaluation of the quality of the RCT (see Appendix I).
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Table 2.1
Summary of Evidence
Lead Author/Yr

Database(s)

Barnason (2017)

TRIP

Level of
evidence/Type
I/SR

TRIP

I/CPG

High/AGREE II

CC

II/RCT

High/CASP

CC

II/RCT

High/CASP

PubMed

I/SR

Moderate/CASP

CC

II/RCT

Moderate/CASP

CINAHL

I/SR&MA

High/CASP

Cochrane

I/SR

High/CASP

Medline

II/RCT

High/CASP

TRIP

I/CPG

High/AGREE II

Barone Gibbs (2021)
Baross (2017)
Chiang (2019)
Dempsey (2018)
Gradidge (2018)
Lee, S. (2020)
Lee, L. (2021)
Perl (2016)
Whelton (2018)

Quality/Tool
High/CASP

Note. CC = citation chased; CPG = clinical practice guideline; MA = meta-analysis; RCT =
randomized controlled trial; SR = systematic review

Construction of Evidence-based Practice
Synthesis of Critically Appraised Literature
Physical Activity
Recommendations. Physical activity (PA) has been demonstrated to be one of the best
nonpharmacological interventions for the prevention and treatment of hypertension. The 2017
ACC/AHA guidelines for hypertension recommend moderate-intensity aerobic physical exercise
90 to 150 minutes per week (Whelton et al., 2018), but a more recent scientific statement from
the ACC/AHA in 2021 (Barone Gibbs et al.) recommended that all Americans get either 150 to
300 minutes per week of moderate-intensity PA, 75 to 150 minutes of vigorous intensity PA, or a
combination of moderate- and vigorous- intensity PA for an equivalent amount of time. These
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recommendations for aerobic exercise can lower SBP by 5 to 8 mmHg in people with
hypertension and by 2 to 4 mmHg in people with normotension (Whelton et al., 2018).
Aerobic Exercise. Walking is a low-cost, safe, and feasible form of aerobic exercise that
is often used as a leisure activity by both men and women (Baross et al., 2017; Dempsey et al.,
2018; Gradidge & Golele, 2018; Lee & Chae, 2020; Lee et al., 2021; Whelton et al., 2018).
Engaging in a walking program increases PA time and decreases sedentary time (Baross et al.,
2017; Dempsey et al., 2018; Gradidge & Golele, 2018), which is beneficial. A single workout can
reduce SBP by -2 to -12 mmHg which can last up to 4 to 16 hours (Barone Gibbs, et al., 2021).
Breaking up sedentary time while at home or at work reduces SBP and DBP significantly, and its
effects last into the evening hours (Dempsey et al., 2018). Over time, the more frequent PA will
reduce SBP and DBP and can prevent progression to hypertension in patients who are at-risk
(Barone Gibbs, et al., 2021; Lee et al., 2020). Activity levels above the 150 to 300 minutes per
week of moderate-intensity PA recommendation show even greater health benefits (Barone
Gibbs et al., 2021). Moderate-intensity PA is the most effective intensity of aerobic exercise to
reduce SBP and DBP (Barone Gibbs et al., 2021; Gradidge & Golele, 2018; Lee & Chae, 2020;
Lee et al., 2021; Whelton et al., 2018). Walking is a form of aerobic exercise that is easily
accessible. As an intervention, walking is likely to reduce BP for various age groups and gender
(Barone Gibbs et al., 2021; Dempsey et al., 2018; Gradidge & Golele, 2018; Lee et al., 2021).
The frequency of walking has the best effect when done three times a week, compared to twice
and four or more times per week (Barone Gibbs et al., 2021; Lee & Chae, 2020). Minutes per
week is a common prescription for PA in general and can be used specifically for walking
(Barone Gibbs et al., 2021; Gradidge & Golele, 2018; Lee et al., 2021; Whelton, et al., 2018).
Pedometer
Using a pedometer helps people with hypertension monitor their step counts and reveals
trends in PA over time (Barone Gibbs et al., 2021). The use of pedometers has been shown to
reduce SBP, and in some studies, reduces it significantly (Chiang et al., 2019; Lee et al., 2021).
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A step goal of 12,000 steps per day has been shown to reduce SBP, in a manner that was
clinically significant, but not statistically significant. The addition of a walking exercise for 30
minutes three days per week with a designated walking rate of greater than 103 steps per minute
reduced SBP and DBP more than a step count goal of 12,000 alone (Chiang et al., 2019). Steps
can be counted using a pedometer or another activity tracker, such as a smartwatch (Barone
Gibbs et al., 2021; Chiang et al., 2019; Lee et al., 2021). Activity trackers objectively measure
steps, distance, and PA duration for all types of activity intensity (Barone Gibbs et al., 2021).
Education
Educating patients with hypertension is crucial to their success in reducing their BP.
Therapeutic patient education (TPE) should include pathophysiology and consequences of
hypertension, self-monitoring of BP (SMBP) at home, and the importance of PA (Barnason et al.,
2017; Perl et al., 2016; Whelton et al., 2018). A structured educational program can help patients
significantly reduce their BP (Perl et al., 2016). TPE should be focused on initiating self-care
behaviors rather than strictly information alone; this includes using teach-back and motivational
interviewing (Barnason et al., 2017; Whelton et al., 2018). The benefits of educated patients
were shown to be directly related to the higher levels of information they obtain and are not due
to health care providers that may be more attentive than others (Perl et al., 2016). Although
some health care providers may spend more time with the patient or may follow a patient’s
hypertension more closely than another health care provider, the higher level of education allows
the patient to be autonomous and to better manage their hypertension.
Pathophysiology and Consequences. Education on the pathophysiology and
consequences of hypertension helps patients understand the importance of reducing their BP. It
is essential to impress upon patients that physical inactivity is one of the main contributors to
developing and continuing hypertension (Whelton et al., 2018). Education should include that
high levels of SBP and DBP are associated with a higher risk of CVD (Whelton et al., 2018), and
CVD is a leading cause of mortality and disability (Barnason et al., 2017). It is important for
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patients to know that hypertension is a main cause of cardiovascular and cerebrovascular
morbidity and mortality (Perl et al., 2016). Simplifying this information to account for lower levels
of health literacy is important (Barnason et al., 2017; Whelton et al., 2018) and can be worded
like the following: high BP is a main contributor to heart disease and stroke and is a leading
cause of death worldwide. Adherence to lifestyle modifications such as PA are essential for the
successful management of hypertension, and this relies heavily on the patient’s knowledge
(Barnason et al., 2017).
SMBP. Home SMBP is the most practical approach to monitor BP in patients who have
hypertension (Whelton et al., 2018). SMBP requires skill by the patient and a calibrated home BP
cuff (Barnason et al, 2017; Whelton et al., 2018). Education about SMBP should focus on proper
cuff size, proper cuff placement, timing of BP readings, and position of the patient during
measurement. It is vital to educate patients how to interpret their home BP so they can get
medical help when needed (Whelton et al., 2018). Instructions for patients regarding SMBP
procedures include remaining still and avoiding smoking, caffeinated beverages, or exercise
within 30 minutes before BP measurements, and ensuring longer than five minutes of quiet rest
before taking the BP measurement. To sit correctly, the patient should sit with their back straight
and supported with their feet flat on the floor with legs uncrossed, and support the arm on a flat
surface, keeping the upper arm at heart level. The bottom of the cuff should be placed just above
the antecubital fossa, or the bend of the elbow. The patient should be instructed to take at least
two readings that are one minute apart in the morning before taking any medications and in the
evening before eating dinner. It is optimal that the patient measures and records their BP daily,
but ideally, a weekly BP measurement should be obtained starting two weeks after a change in a
treatment regimen and during the week before an office visit (Whelton et al., 2018). Guidance on
SMBP should be given along with follow-up in person or by telehealth to improve outcomes
(Barnason et al., 2017).
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Importance of Physical Activity. Patients will need a clear expectation of how PA will
affect their BP because a lesser outcome than expected can cause dissatisfaction and
decreased motivation to maintain the new PA regimen (Whelton et al., 2018). Patients should be
educated that a minimum of three 30-minute PA sessions per week should be completed, and
ideally, patients should strive to exercise 90 to 150 minutes per week (Barone Gibbs et al., 2021;
Perl et al., 2016; Whelton et al., 2018). Education can include what the best evidence has shown
to decrease BP in walking programs. Walking without other intervention can decrease SBP and
DBP in a clinically significant way (Chiang et al., 2019; Gradidge & Golele, 2018). SBP and DBP
can be decreased significantly by breaking up sedentary time with bouts of walking, which is
feasible at most workplaces (Dempsey et al., 2018). This education about brief walking bouts
throughout the day may encourage patients who are concerned about setting aside time to walk
to achieve the weekly minute goal of 90 to 150 minutes. Education on the expected decreases in
SBP and DBP can properly prepare patients on what to expect and can therefore increase
adherence to a walking program.
Recommendation for Best Practice
Based on the synthesis of the literature and the feasibility of implementation at the project
site, the most appropriate intervention is a walking program that utilizes pedometers/activity
trackers and education with follow-up. Walking should be done at a moderate intensity for a total
of 90 to 150 minutes weekly. Pedometers or activity trackers should be used to monitor step
counts and PA. Education on pathophysiology and consequences of hypertension, SMBP, and
the importance of PA should be given, and follow-up should occur to reinforce education.
An additional extensive literature search was completed after data were analyzed to find
potential new findings in the literature. Findings from this search are discussed in Chapter 5.
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CHAPTER 3
IMPLEMENTATION OF PRACTICE CHANGE
Information about the participants, setting, comparison, intervention, proposed outcomes,
and projected timeline are included in this chapter. Details regarding protection of human
subjects are also included.
The implementation of practice change included a walking program that increased in total
minutes per week over the course of eight weeks. Education was provided at baseline, and a
pedometer mobile application or smartwatch was used to track the number of steps the
participant takes per day.
Participants and Setting
This project was implemented at a large family practice office in Northwest Indiana. Two
physicians and three nurse practitioners in the office were key stakeholders. Recruitment of
participants was done at the conclusion of a scheduled office visit. Inclusion criteria were people
18 years or older, those who had the ICD-10 code I10 essential (primary) hypertension, and had
access to a smartphone or smartwatch. Exclusion criteria included those who were pregnant,
younger than 18 years, people who were unable to walk at a moderate intensity, people who
were at moderate or high cardiac risk as determined by their provider, and those who did not
have the mental capability to follow program requirements or log their information.
Pre-Intervention Group Characteristics
Every participant in this project had the ICD-10 code I10 essential (primary) hypertension
in their electronic medical record (EMR). The participants’ ages ranged from 31 to 66 years.
There were 14 males and 12 females.
Intervention
Preparing and planning for the intervention began once discussions with key
stakeholders about project site feasibility were synthesized with the recommendation for best
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practice. The project manager discussed the project’s design with the key stakeholders.
Prevalence data for ICD-10 code I10 Essential (primary) hypertension for the five providers at
the site that are included in this project was sought from the clinical manager. The project
manager briefly described the important details of the project design to all key stakeholders in
separate one-on-one meetings and developed a 21-slide PowerPoint detailing the entire project
design (refer to Appendix J). The presentation was sent by email, and key stakeholders were
encouraged to review it on their own time unless they preferred the project manager review it inperson. The project manager followed up with key stakeholders and determined if they had
questions, suggestions, or comments. One provider requested clarification about the recruitment
process, which was provided by the project manager. It was determined that the project manager
would be present at the clinical site to recruit participants at the end of their scheduled provider
visits if they had the ICD-10 code I10 in their EMR. Trials of the selected mobile applications
were completed to determine ease of use and validity in step counts. Two free mobile
applications, each compatible with a certain smartphone, were determined to be easy-to-use and
valid within 3% of actual step counts.
To implement the practice change, participants were recruited at the end of their
scheduled office visits with their providers. The project manager met with them individually in the
private room to briefly explain the project to the patient and determine their interest in
participating. Every potential participant was informed that their decision to participate had no
impact on the care given by their provider. Once a person decided to participate, the project
manager educated the participant and provided handouts as outlined in the paragraphs below.
This was considered the baseline day. In some instances when the current room was needed for
scheduled patient visits, the project manager led the participant to another private room across
the office.
The participants were educated that essential (primary) hypertension is not caused by
another medical condition and that physical inactivity is one of the most common reasons for the
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development of hypertension. Education included the consequences of hypertension including
having a higher risk of developing CVD, and that CVD is a leading cause of death and disability.
It was explained that hypertension is a main cause of heart and brain death and disability.
Proper home SMBP technique was taught on baseline day and was reinforced when
meeting with the project manager again at the 4-week visit. As was standard of care at the
project site, participants were encouraged to take their BP once per week either at home or at a
location convenient to them, but this was not required for the project. Education included
avoidance of smoking, caffeine, and exercise for at least 30 minutes before taking their BP. The
project manager provided guidance about the proper cuff size, proper cuff placement, and the
position of quietly sitting with feet flat on the floor, legs uncrossed, and resting for 5 minutes
before BP was measured. The participant was instructed not to talk during BP measurement, to
sit with their back straight, and to have the arm supported at heart level.
The participants were educated that regular walking at a moderate intensity helps to
maintain a healthy blood pressure and can reduce blood pressure in patients with hypertension.
They were taught that evidence has shown that walking at a moderate intensity can reduce SBP
and DBP significantly, and that breaking up sedentary time with short bouts of walking is
effective in reducing SBP and DBP as well. Participants were informed that walking has been
shown to reduce SBP by 9 mmHg and DBP by 6 mmHg, which improves cardiovascular health
and reduces risk of heart disease, stroke, and kidney disease.
Handouts were given to participants to log their minutes per week of walking, their daily
step counts, and their weekly BP measurement; the handouts also served as visual
reinforcement of the education given by the project manager on baseline day. A handout was
created to give participants ideas for BP measurement locations and for walking locations in
case the weather was not feasible for outdoor walking. Participant handouts included the Minutes
Per Week of Moderate-Intensity Walking Log Sheet (Appendix A), the patient education sheet
(Appendix B), the Daily Steps and Weekly Blood Pressure Log Sheet (Appendix D), and the
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Ideas for Walking sheet (Appendix K). Since weekly BP measurements are standard of care for
patients with hypertension at this project site, the Daily Steps and Weekly Blood Pressure Log
Sheet included an area to record these BPs, which was not part of the intervention for this
project.
Moderate-intensity walking was described to the participants in three ways to encourage
participant autonomy by choosing their preferred method of monitoring their intensity. One way
was to explain that moderate-intensity walking is achieved when a person walks an average of
100 steps per minute (Chiang et al., 2019; Tudor-Locke et al., 2019). If a participant chose to
walk on a treadmill, they were instructed to walk at a 2.5 to 3.5 miles per hour pace. Lastly,
another way was explained as a brisk walking rate that keeps their heart rate between 64% and
76% of their maximum heart rate. The CDC’s equations were used to estimate the participants’
age-related minimum and maximum heart rate in beats per minute (bpm) that reflects moderateintensity exercise. Their age in years was subtracted from 220 and then multiplied by 0.64 to
calculate the minimum heart rate. Next, their age in years was subtracted from 220 and then
multiplied by 0.76 to calculate the maximum heart rate. This calculation was completed by the
project manager, with the individualized range of heart rates by age provided to the participants.
Participants who chose to count their heart rate were shown how to count either a radial or
carotid pulse over the course of a minute.
The participants’ BPs were measured by the project manager at every visit using a Welch
Allyn Tycos 767 Wall Mounted Sphygmomanometer and 3M Littmann Classic III stethoscope.
At the week eight visit, the participants’ log sheets of step counts, weekly BP
measurements, and minutes per week of moderate-intensity PA were collected. Final BP was
measured. A satisfaction survey (refer to Appendix L) was given at this visit to determine the
likelihood of adherence to the walking program for present participants and future patients.
Participants were also provided positive reinforcement for their efforts and encouragement to
continue or increase their level of PA moving forward.
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Comparison
Participants served as their own comparison. Their week eight SBP, DBP, and number of
minutes of moderate-intensity walking were compared to their baseline SBP, DBP, and number
of minutes of moderate-intensity walking. Baseline SBP ranged from 112 to 166 mmHg and
averaged 136 mmHg. Baseline DBP ranged from 62 to 110 mmHg and averaged 83 mmHg. At
baseline, the number of minutes engaged in moderate-intensity PA per week was between zero
and 315 minutes, with zero being the most common number of minutes reported at baseline.
Outcomes
At four weeks, the participants’ SBP and DBP were measured. At the conclusion of the
eight-week intervention, SBP and DBP were measured. The number of minutes of PA data and
daily step counts were obtained from participants’ logs at the week eight visit.
For primary outcomes, both the BP measurements and the minutes of PA per week data
were analyzed separately using a Wilcoxon Signed Rank Test. For secondary outcomes, the
average weekly step count data was analyzed using a Wilcoxon Signed Rank Test. SPSS
Statistics was used to assess the outcomes, including the reliability and validity of the outcomes.
Participants were grouped into two categories to control for medication changes; one category
was those participants who had a change in their BP medications during the intervention period
and the other category was those participants who did not have a change in their BP medications
during the intervention period.
Time
The timeline of this project is presented in Appendix M. Recruiting participants marked
the beginning of the implementation phase of this project. Recruitment began August 25, 2021
and continued through September 8, 2021. Each participant was required to complete eight
weeks of the walking program for data to be used for analysis. Project implementation was
scheduled to begin as soon as possible in order to recruit between 20 and 40 participants before
the busy holiday season. Participants returned to the office at four weeks into the program for a
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follow-up BP measurement. Education was reinforced at this time and questions were answered.
This range of time was between September 23, 2021 and October 4, 2021.
At eight weeks, between October 22, 2021 and November 8, 2021, the participants were
scheduled to come to the office for a post-intervention BP measurement and return their
completed log sheets for data analysis. Participants were given a satisfaction survey to complete
at this visit.
Protection of Human Subjects
Protection of human subjects was this project manager’s priority throughout the project.
The project manager completed education and training about protection of human subjects
included in the Doctor of Nursing Practice curriculum and completed an online ethics training
course created by the Collaborative Institutional Training Initiative (CITI) on April 1, 2020 (see
Appendix O). The project was determined to be exempt from Valparaiso University’s Institutional
Review Board on July 16, 2021. The site facilitator confirmed that this project did not require IRB
approval (see Appendix P). Confidentiality of participants’ identifying information was upheld by
way of double-locked laptop and Excel sheet. The separate passwords were known only by the
project manager. Participation in the project was completely voluntary and every potential
participant was informed that their decision to participate would not affect the care given by their
provider. An informational sheet (see Appendix N) was provided to participants that informed
them about what they were being asked to do and that they could stop participating at any time
without penalty. The educational sessions were held in a private location with the door closed. All
information that was obtained in this project was reported without using any identifying
information.
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CHAPTER 4
FINDINGS
This chapter presents the results of the data analysis for the primary and secondary
outcomes and includes the quantitative satisfaction survey results and open-ended qualitative
findings. Demographic information for the participants and key project findings are presented.
Overall, the participants in this EBP project significantly decreased their SBP and DBP and
significantly increased their minutes per week of moderate-intensity walking. The participants
reported they were satisfied with the walking program, and many stated they planned to continue
walking following the completion of the project.
The primary outcome data met three out of four assumptions for parametric testing:
normally distributed data, interval level data, and independence. Homogeneity of variance was
not demonstrated in this data. Therefore, the Wilcoxon Signed Rank Test was chosen to
complete the data analysis on the primary outcomes because it is the nonparametric equivalent
to a dependent t-test. Descriptive statistics were used for the secondary outcome due to a small
sample size that provided complete data for daily step counts.
Participants
Demographic information that was collected from each participant included age, gender,
and BP medication information (shown in Table 4.1). Twenty-six participants were recruited, 12
of which were females (46.15%). The mean age of the 26 participants that were recruited was 50
years (SD= 9.8), ranging from 31 to 66 years. Twenty-one participants were on at least one BP
medication at baseline. Thirteen participants completed the intervention (see Table 4.1). There
were four females (30.77%) and nine males (69.23%). The mean age was 52.23 (SD = 11.23)
years with a range of 31 to 66 years. Ten participants were on at least one BP medication
(76.92%), and three participants (23.08%) had a BP medication change during the intervention
period. There were no statistically significant differences in the gender or age of the participants
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who completed the project and those who did not shown by a chi-square analysis (gender: p =
0.116) and t-test (age: p = 0.5426).

Table 4.1
Descriptive Demographic Data for Baseline and Week Eight Participants
Data type
Number of Participants

Baseline

Week eight

26

13

Attrition Rate

50%

Age (years)
Mean (SD)

50 (9.8)

52.23 (11.23)

31-66

31-66

Female

12 (46.15%)

4 (30.77%)

Male

14 (53.85%)

9 (69.23%)

No BP medications

5 (19.23%)

3 (23.08%)

Taking BP medications

21 (80.77%)

10 (76.92%)

One BP Medication

13 (50%)

5 (38.46%)

Two BP Medications

7 (26.92%)

5 (38.46%)

Three BP Medications

1 (3.85%)

0 (0%)

Range
Gender

Note. BP = blood pressure; SD = standard deviation

Changes in Outcomes
The PICOT question of this project was: does an 8-week (T) structured walking program
utilizing a smartwatch for step counts and education (I) reduce BP and increase the number of
minutes of weekly moderate-intensity walking (O) in adults aged 18 years or older with essential
hypertension (P) compared to baseline (C)? Therefore, the primary outcomes include SBP, DBP,
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and number of minutes of weekly moderate-intensity walking. The secondary outcome was
average daily step count categorized by week.
Statistical Testing and Significance
Statistical Package for Social Sciences 25 (SPSS25) was the program used to complete
data analysis. Primary outcome data did not meet all four assumptions that are required to use
parametric testing. Because the project was a within-group design, the primary outcome data
were analyzed using the Wilcoxon Signed Rank Test. For the secondary outcome data, only five
participants provided complete step count data, so these data were analyzed using descriptive
statistics. For the satisfaction survey, descriptive statistics were used to analyze quantitative
data.
Findings
Table 4.2 presents the data collected from each participant at baseline and at their final,
week eight visit. If a participant had a medication adjustment during the intervention period, it is
noted in the last column. There were three participants who had medication adjustments during
the intervention.
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Table 4.2
Participant Data for Primary Outcomes

Participant

Baseline BP

1

134/72

Baseline
number of
minutes of
moderateintensity
walking
30

-

Week eight
number of
minutes of
moderateintensity
walking
-

2

132/78

120

126/82

169

No

3

124/74

315

128/74

590

No

4

150/100

210

-

-

-

5

140/99

0

-

-

-

6

130/80

60

-

-

-

7

142/84

30

124/78

370

Yes

8

126/82

60

-

-

-

9

144/90

0

140/80

100

No

10

132/70

0

-

-

-

11

124/72

0

124/62

147

No

12

120/70

90

-

-

-

13

130/74

35

124/82

165

Yes

14

128/80

30

114/74

75

No

15

134/86

60

110/70

215

No

16

148/72

0

144/70

75

No

17

144/98

0

-

-

-

18

135/85

0

128/76

170

No

19

134/82

10

-

-

-

20

164/106

100

118/78

0

Yes

Week eight
BP

Medication
adjustments
-
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Participant

Baseline BP

21

138/88

Baseline
number of
minutes of
moderateintensity
walking
180

-

Week eight
number of
minutes of
moderateintensity
walking
-

22

132/78

60

-

-

-

23

112/62

0

116/62

420

No

24

138/78

0

-

-

-

25

142/110

0

-

-

-

26

166/100

0

130/88

50

No

Week eight
BP

Medication
adjustments
-

Note. BP= blood pressure; “-“ = no data.

Primary Outcomes
Systolic Blood Pressure. The overall mean baseline SBP for the participants was
136.27 (SD = 12.1) mmHg and ranged from 112 to 166 mmHg. For the participants who
completed the intervention, the mean baseline SBP was 137.15 (SD = 15.53) mmHg and ranged
from 112 to 166 mmHg. At week eight, the overall mean SBP was 125.08 (SD = 9.61) and
ranged from 110 to 144 mmHg (see Table 4.3). The data analysis including all participants who
completed the intervention demonstrated a statistically significant difference between baseline
SBP and week eight SBP (p = .007). This means the participants’ SBPs reduced significantly
after the intervention. Including the three participants that had a BP medication change during
the intervention period could affect the results. However, when the analysis was completed
without these three participants’ data, the results were still significantly different (p = .036) as
shown in Table 4.4. This means that the SBP was reduced significantly regardless of a BP
medication change during the intervention.
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Diastolic Blood Pressure. The overall mean baseline for the participants’ DBP was
83.46 (SD = 12.3) mmHg and ranged from 62 to 110 mmHg. For the participants who completed
the intervention, the mean baseline DBP was 81.77 (SD = 12.04) mmHg and ranged from 62 to
106 mmHg. At week eight, the overall mean DBP was 75.08 (SD = 7.64) with a range from 62 to
88 mmHg (see Table 4.3). The data analysis including all participants who completed the
intervention demonstrated a statistically significant difference between baseline DBP and week
eight DBP (p = .021). This means the participants’ DBPs reduced significantly after the
intervention. Including the three participants that had a BP medication change during the
intervention period could affect the results. However, when the analysis was completed without
these three participants’ data, the results were still significantly different (p = .025) as shown in
Table 4.4. This means that the DBP was reduced significantly regardless of a BP medication
change during the intervention.
Minutes Per Week of Moderate-Intensity Walking. At baseline, the reported number of
minutes engaged in moderate-intensity PA for all participants ranged from zero minutes weekly
to 315 minutes weekly. The overall baseline mean number of weekly minutes was 53.46 minutes
(SD = 78), and the baseline mean for those who completed the intervention was 53.07 (SD =
88.33) (see Table 4.3). Eleven out of 26 of the participants at baseline reported zero minutes
weekly of moderate-intensity PA. At baseline, over 75% of all participants engaged in less than
90 minutes of moderate-intensity PA weekly which is below the 2017 ACC/AHA
recommendations of 90 to 150 minutes per week.
At week eight, the reported number of minutes engaged in moderate-intensity walking for
participants who completed the intervention ranged from zero minutes weekly to 590 minutes
weekly. The overall mean number of weekly minutes was 195.85 (SD = 168.09) minutes (see
Table 4.3). The data analysis including all participants who completed the intervention showed a
statistically significant difference between baseline reported number of minutes of moderateintensity walking and week eight reported number of minutes of moderate-intensity walking (p =
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.005) as shown in Table 4.4. This means that participants who completed the intervention
significantly increased their reported number of minutes of weekly moderate-intensity walking
after the intervention. At the final visit, 30.7% of participants reported engaging in less than 90
minutes during week eight, which decreased from 75% at baseline. At week eight, 69% of
participants reported engaging in greater than 90 minutes of moderate-intensity PA weekly, and
53.8% of participants reported engaging in greater than 150 minutes per week of moderateintensity walking. Both meet or exceed the 2017 ACC/AHA recommendations of 90 to 150
minutes per week.

Table 4.3
Descriptive Analysis for Baseline and Week Eight Participants

Data type
Mean SBP (mmHg)
Range
Mean DBP (mmHg)
Range
Mean # of Weekly Minutes
of MIW
Range

136.27, SD = 12.1

Baseline for
participants who
completed
intervention (n = 13)
137.15, SD = 15.53

Week eight for
participants who
completed
intervention (n = 13)
125.08, SD = 9.61

112-166

112-166

110-144

83.46, SD = 12.3

81.77, SD = 12.04

75.08, SD = 7.64

62-110

62-106

62-88

53.46, SD = 78

53.07, SD = 88.33

195.85, SD = 168.09

0-315

0-315

0-590

Overall Baseline
(n = 26)

3 (23.08%)
Participants With BP
Medication Change During
Intervention
Note. # = number; MIW = moderate-intensity walking; SD = standard deviation
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Table 4.4
Data Analysis of Primary Outcomes
Variable
SBP

Null hypothesis
The median of
differences between
BaselineSYS and
Wk8SYS equals 0.

Test
Significance
Decision
Related.007 (n = 13)
Reject the null
Samples
.036 (n =10)
hypothesis.
Wilcoxon
Signed Rank
Test
DBP
The median of
Related.021 (n = 13)
Reject the null
differences between
Samples
.025 (n =10)
hypothesis.
BaselineDIA and
Wilcoxon
Wk8DIA equals 0.
Signed Rank
Test
# minutes of
The median of
Related.005
Reject the null
MIW
differences between
Samples
hypothesis.
Baseline#Min.Mod.Walk Wilcoxon
and
Signed Rank
Wk8#Min.Mod.Walk
Test
equals 0.
Note. SBP and DBP outcomes show the results for all participants who completed the
intervention as shown by n = 13, and the results for the 10 participants that did not have a
change in BP medications during the intervention as shown by n = 10. SBP = systolic blood
pressure; DBP = diastolic blood pressure; # = number; MIW = moderate-intensity walking.

Secondary Outcome
Average Daily Step Count. Data reported by the five participants who provided
complete step count data showed a mean of 8205.69 (SD = 3832.65) during week one of the
intervention and a mean of 10059.91 (SD = 4042.75) during week eight of the intervention (see
Table 4.5). There were not enough participants who reported complete step count data to run a ttest to test for significance. However, the mean difference shows that there was an increase in
average daily step counts from week one to week eight in the five participants that completed the
step count data.
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Table 4.5
Secondary Outcome: Average Daily Step Count
Standard
Week

Range

Minimum

Maximum

Mean

Variance
deviation

One

9466.57

5411.71

14878.29

8205.6856

3832.64582 14689173.990

Eight

10056.29

6040.86

16097.14

10059.9094 4042.75197 16343843.512

Note. Values are step counts.

Satisfaction Survey
Participant satisfaction was measured with 5-point Likert scale items that had a range of
1= strongly disagree to 5=strongly agree, including a middle neutral option (See Appendix L).
Mean scores above 2.5 reflect higher satisfaction whereas scores below 2.5 reflect lower
satisfaction. A reliability analysis was performed on the satisfaction survey that was created for
this project, and it determined a Cronbach alpha value of 0.770, indicating strong internal
consistency between survey items. The median values for items 1, 2, 4, and 5 were 5.00, and
the median value for item 3 was 4.00 (see Table 4.6). This indicates that participants “strongly
agreed” with positive statements about the program.
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Table 4.6
Satisfaction Survey Analysis
Survey item
“I enjoyed this

Mean (SD)

Median

Mode

Range

4.69 (0.48)

5.00

5.00

4.00-5.00

4.69 (0.63)

5.00

5.00

3.00-5.00

4 (0.82)

4.00

4.00

3.00-5.00

4.77 (0.44)

5.00

5.00

4.00-5.00

4.69 (0.48)

5.00

5.00

4.00-5.00

walking program.”
“This program was
easy to follow.”
“I notice a
difference in my
health after
completing this
walking program.”
“I plan to continue
walking to reduce
my blood
pressure.”
“I would
recommend this
program to a
friend or family
member.”
Note. SD = standard deviation.

Some open-ended qualitative findings of the satisfaction survey included statements such
as “this has been a learning experience that shows walking can improve your health without
major exercise,” and “this program challenged me to make decisions to improve my health by
walking several times a week and watching food choices as well”. Other statements included
“thanks! It was good to be accountable (at times)” and “it was hard to start, but as the weeks
went on, it got easier to go harder and longer”. One participant noted the program was motivating
for them and wrote “I feel better”. Another participant said it was “difficult to track in two places”
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and offered an idea of having more reminders and a list of at-home BP devices for a quick
reference to give future patients with HTN. Another participant said, “day to day fluctuations
(things happening) make it difficult to stay on course”.
In conclusion, the primary outcomes of SBP and DBP were significantly reduced, and the
primary outcome of minutes per week of moderate-intensity walking was significantly increased
after this intervention. The secondary outcome of average daily step counts increased overall
from week one to week eight. Participants reported overall satisfaction with the walking program,
and 4.77 out of 5 reported they planned to continue walking to reduce their BP.
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CHAPTER 5
DISCUSSION
The PICOT question for this EBP project was: does an eight-week (T) structured walking
program utilizing a smartwatch for step counts and education (I) reduce BP and increase the
number of minutes of weekly moderate-intensity walking (O) in adults aged 18 years or older with
essential hypertension (P) compared to baseline (C)? An eight-week structured walking program
was implemented that included daily step count tracking and education given at baseline and at
a four-week follow-up visit. The weekly goal for moderate-intensity walking increased from at
least 90 minutes during weeks one and two, to at least 120 minutes during weeks three and four,
and to at least 150 minutes during weeks five through eight.
The findings of the statistical analyses for the primary and secondary outcomes will be
explained in this chapter. The strengths and limitations of this EBP project will be discussed.
Relevance of the EBP model that was selected to guide the implementation of this project will be
evaluated, and future recommendations are explored.
Explanation of Findings
Primary Outcomes
Systolic Blood Pressure. The data analysis for all participants who completed the
intervention demonstrated a statistically significant difference between baseline SBP and week
eight SBP (p = .007). Even after three participants’ data were removed due to BP medication
change during the intervention period, the SBP difference was still statistically significant (p =
.036). This means the participants’ SBPs decreased significantly after the structured walking
intervention, which is consistent with evidence found in the literature (Barnason et al., 2017;
Barone Gibbs et al., 2021; Dempsey et al., 2018; Gradidge & Golele, 2018; Lee et al., 2020; Lee
et al., 2021; Whelton et al., 2018). A systematic review and meta-analysis demonstrated that a
moderate-intensity walking program lasting eight to 11 weeks produced the largest reduction in
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BP compared to a higher or lower intensity and shorter or longer duration (Lee et al., 2020).
Another RCT showed significant reductions in SBP in an intervention group who walked at a
moderate intensity on treadmills for 30 minutes three times per week for 12 weeks (Gradidge &
Golele, 2018).
In contrast, Baross et al. (2017) showed clinically significant, but not statistically
significant, reductions in SBP in a walking group that walked on a treadmill for 30 minutes four
times a week for six weeks. The intervention for this RCT (Baross et al., 2017) lasted only six
weeks whereas the intervention for this EBP project lasted eight weeks. An eight-week
intervention has been shown to be an ideal duration to significantly reduce SBP and DBP (Lee et
al., 2020). Another RCT showed a clinically, but not statistically, significant reduction in SBP for a
moderate-intensity walking group that had a goal of 12,000 steps per day (Chiang et al., 2019).
This RCT’s intervention lasted eight weeks, but the moderate-intensity walking duration was only
90 minutes per week throughout the intervention. This may account for the nonsignificant
reduction in SBP in Chiang et al. (2019) in comparison to this EBP project because this EBP
project increased the minutes per week of moderate-intensity walking requirement above 90
minutes for weeks five through eight. Duration of at least 150 minutes or greater per week of
moderate-intensity aerobic exercise has been shown to reduce SBP more than only 90 minutes
per week (Whelton et al., 2018).
This EBP project utilized self-monitoring of BP, printed materials, and follow-up to
increase adherence. This was similar to a systematic review that showed these interventions
improved participants’ BP (Barnason et al., 2017). In a RCT, a structured educational program
was given to two groups at different times. Group G-I received education at baseline, and Group
G-II received education at six months. Group G-I had statistically significantly lower SBP at six
months than Group G-II at the six-month visit. At 12 months, both groups showed similar
reductions in SBP (Perl et al., 2016). This is consistent with this EBP project’s education at
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baseline via verbal and visual modes to enhance learning and increase adherence to the walking
program.
Diastolic Blood Pressure. The data analysis for all participants who completed the
eight-week intervention demonstrated a statistically significant difference between baseline DBP
and week eight DBP (p = .021). Even after three participants’ data were removed due to BP
medication change during the intervention period, the DBP difference was still statistically
significant (p = .025). This means the participants’ DBPs decreased significantly after the
structured walking intervention, which is consistent with evidence found in the literature
(Barnason et al., 2017; Barone Gibbs et al., 2021; Dempsey et al., 2018; Gradidge & Golele,
2018; Lee et al., 2020; Lee et al., 2021; Whelton et al., 2018).
A structured educational program reduced DBP in one RCT, but the reduction was not
statistically significant (Perl et al., 2016), which is not consistent with this project’s significant
reduction in DBP. In the RCT, a structured educational program given at baseline for Group G-I
showed nonsignificant reductions in DBP at six months into the intervention. Group G-II who
received the structured educational program at six months showed nonsignificant reductions in
DBP from baseline at six months (Perl et al., 2016). The reductions in DBP were not statistically
significantly different between the groups at 12 months. This is somewhat consistent with this
EBP project’s education at baseline via verbal and visual modes to enhance learning and
increase adherence to the walking program; however, this EBP project showed significant
reductions in DBP. Another RCT showed nonsignificant reductions in DBP in a walking group
that walked on a treadmill for 30 minutes four times a week for six weeks when compared to a
control group (Baross et al., 2017). However, the RCT lasted only six weeks. This EBP project
lasted eight weeks, which was shown in Lee et al. (2020) to be an ideal duration to significantly
reduce SBP and DBP. Another RCT showed a clinically, but not statistically, significant reduction
in DBP for a moderate-intensity walking group that had a goal of 12,000 steps per day. This
intervention’s duration was 90 minutes per week for eight weeks (Chiang et al., 2019), which
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may account for the nonsignificant reductions in DBP in this RCT. The increased minutes per
week of moderate-intensity walking in this EBP project was a minimum of 150 minutes during
weeks five through eight, which may account for this project’s significant reductions in DBP.
Minutes Per Week of Moderate-Intensity Walking. The implementation of this EBP
project included a minimum of 90 minutes per week of moderate-intensity walking in weeks one
and two, a minimum of 120 minutes per week in weeks three and four, and a minimum of 150
minutes per week in weeks five through eight. This recommendation was based on two
guidelines from the literature that recommended either 90-150 or 150-300 minutes per week of
moderate-intensity PA (Barone Gibbs et al., 2021; Whelton et al., 2018). Gradidge & Golele
(2018) demonstrated an increase in moderate-vigorous PA by patient report in the intervention
group, which is consistent with the significant increase in minutes per week of moderate-intensity
walking shown in this EBP project. This EBP project was a structured walking program that
provided goals to every participant for weekly minutes of moderate-intensity walking that
increased over eight weeks, which likely contributed to participants’ significant increase in actual
walking. Follow-up visits also served to encourage adherence and as a reminder about the
walking goals for the participants which was consistent with the findings in Barnason et al.
(2017).
Secondary Outcome
Average Daily Step Count. Only five participants provided complete data on daily step
counts, therefore descriptive analysis was used to analyze this data. Participants who did not
provide complete step count data reported that lack of time and added effort were reasons they
did not track their step counts. This EBP project did not specify a daily step count goal for the
participants as was done in Chiang et al. (2019) which had a goal of 12,000 steps per day.
However, all participants in this EBP project were encouraged to utilize a pedometer to measure
their daily step counts. Barone Gibbs et al. (2021) noted that wearing an activity tracker, such as
the smartwatch used in this project, helped participants stay aware of their PA, which increased
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their likelihood of engaging in PA. The use of a pedometer was shown to reduce SBP
significantly in Lee et al. (2021) which is consistent with what this project demonstrated in the
portion of the participants who provided complete step count data.
Additional Literature Search
An additional extensive literature search was completed after data were analyzed to find
potential new findings in the literature. Two new statements from the AHA were discovered using
similar search criteria as described in chapter 2. The first scientific statement by Jones et al.
(2021) reported similar recommendations that those with stage 1 HTN should only be given
lifestyle modifications such as PA. An important additional recommendation was given for
patients who are not at goal (<130/<80 mmHg) after six months of lifestyle modifications only;
medication intervention should be considered at that time (Jones et al., 2021). The second
science advisory emphasized that PA continues to be a therapeutic intervention that is costeffective and as efficacious as some common cardiovascular medications (Kris-Etherton et al.,
2021). Patients who received counseling to increase PA showed a 42% greater likelihood to be
more physically active than patients who received no counseling (Kris-Etherton et al., 2021). A
statement from the ACC and AHA in 2019 increased the minimum minutes per week of
moderate-intensity PA recommendation to 150 minutes per week or 75 minutes per week of
vigorous-intensity PA which differed from the 2017 ACC/AHA guidelines that recommended 90 to
150 minutes per week of moderate-intensity PA (Kris-Etherton et al., 2021; Whelton et al., 2018).
Strengths and Limitations of the DNP Project
Strengths
The project manager believes the accountability portion of this project is what helped
participants adhere to the walking requirements and ultimately what led to the reduction in their
BPs. A few participants commented at their final visit that having the accountability is what kept
them going. The follow-up visits at four weeks, along with the log sheets that participants were
asked to fill out at home throughout the intervention period, helped to increase accountability.
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The ease of the intervention played a large role in the success of this project. Walking is
an exercise option available to almost everyone and is inexpensive to implement. People may
believe they need to complete drastic exercises to improve their BP so they may feel
discouraged to perform any exercise. Therefore, the strong evidence base supporting walking as
a viable option to help reduce BP enhances its appeal. Walking can be done alone, with other
people, inside malls, outside in nature or downtown cities, inside workout gyms, or at
workplaces. The possibilities are endless for places to walk at moderate intensity to help reduce
BP. Two participants reported ‘feeling better’ when they walked which encouraged them to
continue. The project manager believes the ease and versatility of the intervention contributed
greatly to this project’s success.
Two key stakeholders were particularly invested in helping this project succeed at this
office. One of them was brought on as a key stakeholder near the end of the development stage
of this EBP project but was incredibly encouraging and welcoming to this project for their
patients. The other key stakeholder was vital to this project being well developed. This
stakeholder was invested from the beginning and provided insight into organizational operations
and offered ideas to implement this project in the office. This project would not have been
possible or as successful without this stakeholder.
The employees at the office where this project was implemented were incredibly kind and
helpful, which made the development and implementation of this project easier and successful.
The project manager is incredibly grateful to them for their efforts and kindness throughout the
project.
Limitations
One of the biggest limitations to this project was that contact information of each
participant was not collected. It was decided by one of the key stakeholders and the project
manager that it would be best to utilize the organization’s reminder system for follow-up visits to
remind participants to come back. The project manager did provide her school email to every

42
participant and pointed it out on the informational sheet (Appendix N) at the baseline visit.
However, at the follow-up visit at four weeks, a few participants reported they did not know how
to contact the project manager. Three participants had reached out to the office when they could
not make a visit, which the project manager greatly appreciated. The project manager made sure
to remind participants at every visit about contacting her through her email address for questions
or comments. Having each participants’ contact information might have led to greater adherence
and less attrition through use of weekly reminders to reach their target minutes per week of
moderate-intensity walking.
Another limitation to this project was the complexity of recording daily step counts. Only
five participants provided complete data for daily step counts. One participant reported the daily
step count recordings were confusing and too much work. In addition to this, most of the
participants had a smartwatch and for those who did not, they had a smart phone that had step
count tracking ability without the need to download a mobile application. A lot of time and effort
was spent finding a suitable and easy-to-use mobile application for the participants to track their
daily step count, and the applications were never used. This mobile application seemed to add
another level of complexity to the project that participants did not want to trifle with since their
smartwatches or smartphones were already capable of tracking their step counts.
Sustainability
The sustainability of this EBP project can be easily implemented at the office with some
changes from the original project design. The project manager developed an action plan
(Appendix Q) for stakeholders and other providers at the office to easily implement this project
during visits with patients who have HTN. It consists of three steps. Step one is to discuss BP
categories with the patient who has HTN to improve the patient’s knowledge of ideal BP targets.
This step also includes education about the effects of HTN on the body. Step two is
recommending the structured walking program. This step would include setting goals for minutes
per week of moderate-intensity walking for each patient, ranging from at least 90 minutes to at
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least 300 minutes per week for maximal benefit. Providers will use critical thinking to determine
appropriate goals. The action plan provides an example of a log sheet that patients can use to
keep track of their weekly minutes. Step three is follow-up. This step consists of having patients
send the log sheet with their minutes per week of moderate-intensity walking and at-home BP via
MyChart message at one month, two months, six months, and one year. These timeframes can
be adjusted as needed per the provider’s discretion. Step three is vital to holding the patient
accountable because it requires them to report back with their progress and efforts.
This action plan was discussed with the key stakeholders of this project, and each
received a printed copy. Three key stakeholders were thrilled to hear about the results of the
EBP project and were planning to implement the action plan with their HTN patients with some
adjustments. One key stakeholder said they would welcome the use of MyChart messages to
help their patients stay accountable. However, when they had asked patients in the past to send
an at-home BP reading to the provider a week after their visit, only a small portion of patients had
done it. This stakeholder noted that it depended on the motivation level of the patient. The other
four key stakeholders were overwhelmed with MyChart messages already so they felt that
patients should instead keep their own log sheet at home to hold themselves accountable. The
practice change will be maintained solely by the providers who are willing to educate their
patients with HTN about this structured walking program that should only take a few minutes of
their time to explain. Four key stakeholders were willing to implement the adjusted action plan.
The follow-up messages via MyChart may not be a feasible option for these providers.
A recommendation for future projects would be to collect participants’ contact information,
whether that be email or phone number. Participants may be hesitant about sharing personal
information so reassurance that it will only be used for the project’s purposes may help ease
hesitation. This may potentially increase adherence and decrease attrition for future projects.
Another recommendation would be to avoid requiring participants to track daily step
counts. This added complexity and stress on participants and ultimately did not provide
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substantive benefit to the intervention. It would be beneficial to only have patients focus on and
track their weekly minutes of moderate-intensity walking. The moderate-intensity walking portion
of this project’s intervention had the strongest evidence base so future projects should focus on
this. Inherent to this recommendation would be to avoid using mobile applications that track step
counts because most people have a smartwatch or smartphone that can perform this, and the
mobile application just adds another barrier to participation.
Relevance for EBP Model
The 2022 Johns Hopkins Nursing Evidence-based Practice (JHNEBP) Model was used to
guide the development and implementation of this project. All seven operational steps within
stage one, ‘Practice Question’, were followed. Recruiting the interprofessional team was easily
completed at this office thanks to the employees. The project manager held the responsibility for
the project leadership; however, one key stakeholder was vital to the success of this project from
start to finish. Reports from the office manager and substantive time spent in the office aided the
project manager in clarifying and describing the problem of patients with HTN. This led to
development and refinement of the EBP PICOT question and determining that there was a need
for the EBP project at this office. Identifying key stakeholders occurred over time in the
development phase of this project. The ‘schedule the team meetings’ step involved one-on-one
meetings with key stakeholders rather than a team meeting because of each of their time
constraints.
In stage two, ‘Evidence’, every step was followed. This strengthened this EBP project by
ensuring all relevant evidence was used, and quality of the evidence was thoroughly evaluated.
Internal and external evidence for this project was found, and each piece of evidence was
appraised for quality and level of evidence. The project manager then summarized the evidence,
synthesized the findings, and developed the best evidence recommendations.
In the last stage, ‘Translation’, all steps were followed as well. Early on, practice settingspecific recommendations were identified, and an action plan was developed. There was support
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from key stakeholders to implement this EBP project with their patients who had HTN. The action
plan was implemented, and outcomes were evaluated. The results of the data analyses were
discussed with the key stakeholders, and the next steps were discussed. ‘Identifying the next
steps’ is one of the final steps in this final stage, which guided the development of sustainability
practices for this project in this office. The findings were disseminated at the office, at the
Wisconsin Nurses Association 2022 Pharmacology and Clinical Update conference in April 2022,
and at Valparaiso University’s Oral Presentations by the Candidates for the Doctor of Nursing
Practice in April 2022.
The JHNEBP model was relevant in every step to guide this EBP project. Although some
steps were obvious or straightforward to the project manager, other steps served to be helpful
guides when planning a large project that had complexities along the way. Although there are
several steps within the JHNEBP model, each step proved beneficial to guide this EBP project.
No changes to the model are recommended at this time.
Recommendations for the Future
Research
There was some evidence that was found in the literature search regarding daily step
counts and BP reduction, however more research could be done on the relationship between
these two variables. This can guide healthcare provider recommendations on whether or not
recording step counts is a useful tool to help patients reduce their BP.
More research needs to be done on the principles of motivation and accountability for
people with HTN. The literature was not searched for use of the change theories, such as the
Health Belief Model, and none of the RCTs used in this EBP project followed any theories or
models that focus on changing behavior. More research should be conducted that uses a model
such as the Health Belief Model to guide people with HTN to change their behavior to a healthier
one. A provider may find it important to change a certain health behavior of a patient, but the
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patient may be less concerned about changing that behavior. Exploring patients’ motivation to
change can be beneficial to this intervention being successful in the future.
Research could also explore accountability for people with HTN. Patients may struggle to
adhere to recommendations from their healthcare provider. Research on the best ways to hold
patients accountable may also lead to this intervention being successful in the future.
Education
Patients need to be educated so that they can make proper decisions with regards to
their health. It is essential that undergraduate students learn about the pathophysiology and
detrimental effects of HTN so that they can in turn, educate their patients. It is vital for
undergraduate students to learn primary and secondary prevention for HTN to help improve the
lives of the patients for whom they care. Knowledge of tertiary prevention is essential because
they will likely encounter patients in an outpatient and hospital setting who require tertiary
prevention strategies such as cardiac or stroke rehabilitation programs and renal dialysis.
The same vital knowledge applies for graduate students, however, knowledge of
guidelines and recommendations for diagnosis and treatment are required for graduate students
to provide their patients with the best care. The most recent BP category recommendations and
best evidence medications to treat HTN should be common knowledge for the graduate student.
Lifestyle modifications should be well known so they can be offered for every patient who has
HTN, whether they require medication or not. Although this project focused only on PA, other
lifestyle modifications include sodium restriction, potassium supplementation, weight loss, a heart
healthy diet such as the DASH diet, and alcohol intake of two standard alcohol drinks per day for
men and one per day for women.
Conclusion
HTN has devastating consequences to a person’s body that can lead to death. Easy-toimplement lifestyle modifications such as a structured walking program have been shown to
reduce BP in patients with HTN, providing an enticing and feasible option to combat this
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worldwide health problem. This EBP project was designed to answer the PICOT question: does
an eight-week (T) structured walking program utilizing a smartwatch for step counts and
education (I) reduce BP and increase the number of minutes of weekly moderate-intensity
walking (O) in adults aged 18 years or older with essential hypertension (P) compared to
baseline (C)? This EBP project had statistically significant decreases in SBP and DBP in people
with HTN by walking at a moderate intensity for a target number of minutes per week. Some
participants walked at work while others walked with friends or family members. Some enjoyed
walking alone outside while others preferred walking on a treadmill. The opportunities are
endless for patients with HTN to implement this structured walking program to help reduce their
BP. Providing a goal for number of minutes to walk each week seemed to have contributed to the
statistically significant increase in reported minutes per week of moderate-intensity walking from
baseline to week eight of this intervention. The increase from 25% of participants at baseline to
69% of participants at week eight who walked at least the minimum of 90 minutes per week at a
moderate intensity as recommended by the 2017 ACC/AHA guideline is promising. Participants
noted the accountability of the project is what encouraged them to continue walking as the weeks
passed. Although only a small number of participants reported complete data for the secondary
outcome of daily step counts, the means increased from week one to week eight without daily
step count goals provided by the project manager. This EBP project’s outcomes were consistent
with the outcomes reported in literature. With some changes to the intervention that were
discussed, this EBP project can be implemented with ease in an office setting to help patients
with HTN reduce their BP.
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ACRONYM LIST
ACC: American College of Cardiology
AGREE II: Appraisal of Guidelines for Research and Evaluation II instrument
AHA: American Heart Association
ASCVD: Atherosclerotic Cardiovascular Disease risk score
BP: blood pressure
CASP: Critical Appraisal Skills Programme
CC: citation chased
CDC: Centers for Disease Control
CINAHL: Cumulative Index to Nursing and Allied Health Literature
CITI: Collaborative Institutional Training Initiative
CPG: clinical practice guideline
CVD: cardiovascular disease
DBP: diastolic blood pressure
EBP: evidence-based practice
EMR: electronic medical record
HTN: hypertension
ICD-10: 10th revision of the International Statistical Classification of Diseases and Related
Health Problems
IRB: Institutional Review Board
JBI: Joanna Briggs Institute
MA: meta-analysis
MIW: moderate-intensity walking
PA: physical activity
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
RCT: randomized controlled trial
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SBP: systolic blood pressure
SMBP: self-monitoring of blood pressure
SPSS25: Statistical Package for Social Sciences 25
SR: systematic review
TPE: therapeutic patient education
TRIP: Turning Research Into Practice
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APPENDIX A
Minutes Per Week of Moderate Intensity Walking Log Sheet
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APPENDIX B
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APPENDIX C
MOBILE APPLICATIONS FOR IPHONE AND ANDROID

Figure C1. Pedometer & Step Counter (Version 2.0.0) for iPhone

Figure C2. Step Tracker – Pedometer Free & Calorie Tracker (Version 1.2.1) for Android
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APPENDIX D
Daily Steps and Weekly Blood Pressure Log Sheet
Date

Step Count

BP (Sys/Dia)
Week 1:
/
Week 2:
/
Week 3:
/
Week 4:
/
Week 5:
/
Week 6:
/
Week 7:
/
Week 8:
/

Note. Dia = diastolic; Sys = systolic blood pressure

Date

Step Count
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APPENDIX E
PERMISSION TO USE JHNEBP MODEL
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APPENDIX F
EVIDENCE TABLE
Evidence Table
Lead Author/
Year/Quality

Purpose/
Design/Sample

Interventions

Measurement/
Outcomes

Results/
Findings

Strengths/
Limitations

Improvements in BP in:
a) SMBP (n = 9)
b) Counseling/ Coaching (n
= 4)
c) Printed materials (n = 1)
(in-person)

Strengths:
Extensive
literature
search.
Ensured rigor
of included
studies.

Level I Evidence
Barnason/
2017/High

Critical analysis
of research
studies about
therapeutic
patient
education for
certain
cardiovascular
conditions,
including
hypertension.
Systematic
Review
67 studies (CVD
populations: 16
for hypertension;
7 for CVD; 9 for
atrial fibrillation;
35 for heart
failure. Barriers
to TPE: 31 for
health literacy; 8

The HTN-focused
studies had the
following
interventions:
a) SMBP either alone
or in combination with
education given
verbally or online or
printed materials (n =
10)
b) Counseling or
coaching weekly,
monthly, or bimonthly
(n = 4)
c) Printed materials/
education workbook, 1
in person and 1 with
bimonthly telephone
counseling (n = 2)

SBP; DBP; BP control;
Use of lifestyle
recommendations;
Medication adherence;
BP logs; Reaching
target BP goal; Action
or maintenance of
change behaviors;
Self-efficacy for BP
control; HBP
knowledge; Refill
adherence.

Interventions that provided
follow-up (in-person or by
telehealth) to support SMBP
had better outcomes than
SMBP alone.
Recommendations include
the following:
-TPE delivery for monitoring
of self-management should
be done by multiple modes
(face-to-face, telephone,
telehealth, or combo)
-Consistent information
about self-management
from healthcare team

Limitations:
Authors note
potential of
missed TPE
articles due to
mixed
terminology
and limitations
in
methodology
in studies
about selfmanagement.
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for cognitive
impairment; 5 for
time)

Barone
Gibbs/ 2021/
High

Focus on patient
groups at mild to
moderate risk of
CVD who are
recommended
only lifestyle
modifications for
HTN. Describe
recommendation
s with regards to
PA based on
average effects
of PA. Guide
clinicians in their
use of PA
interventions.
Guideline

-Self-management
education should be
focused on initiating selfcare behaviors rather than
information alone. (Teach
back, motivational
interviewing).
-Comprehensive
interventions addressing the
process of selfmanagement can be more
effective for patients to take
on self-care behaviors.
-

-

Recommendations for
aerobic exercise for all
Americans:
a) 150-300 min/week of
moderate-intensity PA, or
b) 75-150 min/week of
vigorous-intensity PA, or
c) a combination of
moderate- and vigorousintensity PA for an
equivalent amount of time.
Aerobic exercise can
reduce SBP and DBP an
average of -4 mmHg and -3
mmHg respectively.
More frequent PA may be
beneficial because a single
workout can reduce SBP by
-2 to -12 mmHg that lasts
for 4-16 hours. It can

Strengths:
Expert peerreviewed.
Disclosures
are clearly
presented.
Limitations:
One PA
recommendati
on is
ambiguous,
but with
reason.
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prevent progression in
patients that are at mildmoderate risk.
Make sure a patient is
medically cleared to engage
in PA; however, most
patients who are prescribed
lifestyle only treatment are
at low enough risk and are
considered safe without
extensive medical
clearance.
Wearable activity trackers
are helpful in the
assessment of PA.
Dempsey/
2018/
Moderate

Discuss
implications of
sedentary
behaviors and
their effects on
BP.
Systematic
Review
11 experimental/
“acute studies”

Interrupting sitting or
sedentary time with
bouts of light- or
moderate-intensity
walking. Two studies
had regular two to
three minute walking
breaks.

SBP and DBP

Reductions in SBP and
DBP varied from 1 to 16
mmHg.
In inactive
overweight/obese adults:
Significant reductions in
SBP and DBP (-14 to -16
mmHg and -8 to -10 mmHg
respectively) when sitting
was interrupted with lightintensity walking.
Sustained reductions in
SBP and DBP with light
intensity (-5 to -6 mmHg
during the day and -2 to -13
mmHg after working hours)
and moderate-intensity (-5

Strengths:
Similar results
were found
across all
studies.
Limitations:
Methodology
not described.
Confidence
intervals are
not included.
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to -6 mmHg after working
hours) walking breaks
throughout the day.
Lee/ 2020/
High

To evaluate how
BP is affected by
aerobic exercise
in adults with
HTN through a
SR and metaanalysis.
Systematic
Review & MetaAnalysis
37 RCTs with
1,813
participants.

20 studies used
walking or running as
intervention. Other
studies used waterbased training or
aerobic dance. Three
times per week was
the most often
frequency. Duration
ranged from 4 to 37
weeks, and 12 weeks
was the most
frequent.

SBP, DBP, HR

Aerobic exercise
significantly reduced both
SBP and DBP by -8.29
mmHg and -5.19 mmHg,
respectively.
Walking and running lead to
-6.96 mmHg reduction in
BP.
Intensity effect:
a) Moderate-intensity: -8.97
mmHg SBP & -5.75 mmHg
DBP
b) Vigorous intensity: -6.85
mmHg SBP & -4.36 mmHg
DBP
c) Low intensity: -2.93
mmHg SBP & -1.62 mmHg
DBP
Exercise frequency effect:
a) 3x/week: -9.16 mmHg
SBP & -5.55 mmHg DBP
b) 4+x/week: -6.96 mmHg
SBP & -4.50 mmHg DBP
c) 2x/week: -6.10 mmHg
SBP & -4.38 mmHg DBP
Duration effect on SBP:
a) 8-11 weeks: -9.12 mmHg
SBP & -5.42 mmHg DBP

Strengths: No
bias reported.
No conflicts of
interest
reported by
authors.
Reported risk
of bias in
articles used
for review.
PRISMA
provided.
ANOVA used.
Strong
literature
search.
Limitations:
None
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Lee/2021/
High

To determine
how walking
affects BP and
HR when it is
used as a PA
intervention.
Systematic
Review
73 individually randomized
parallel group
trials with 5,763
participants in 22
countries. Ages
were 16-84
years.

Walking on a treadmill
without stairs or uphill
(n=18), outdoor
walking (n=17), brisk
walking (n=16), and
Nordic walking (n=6).
Comparisons were
non-exercise and nonintervention controls.

SBP, DBP, HR.
Measuring intensity:
maximum HR,
VO2max, walking
distance per hour, per
day, or per second,
Borg Scale of
Perceived Exertion,
percentage of HR
reserve.

b) 12-23 weeks: -8.77
mmHg SBP & -4.84 mmHg
DBP
c) 24+ weeks: -8.24 mmHg
SBP & -7.15 mmHg DBP
d) 4-7 weeks: -3.04 mmHg
SBP & -5.42 mmHg DBP
SBP reduced by an average
of 4.11 mmHg and DBP
reduced by an average of
1.79 mmHg in those who
walked versus no
intervention.
Walking interventions show
moderate certainty to
reduce SBP (MD= 4.41)
and DBP (MD= 3.01) in
adults that are 40 years of
age or younger.
Walking interventions show
low certainty to reduce SBP
(MD= 3.79) and DBP (MD=
1.74) in adults that are 41 to
60 years of age, and to
reduce SBP (MD=4.30) and
DBP (MD= 1.33) in adults
who are older than 60
years.
Duration ranged from 10 to
845 minutes per week with
an average of 153 minutes
per week.

Strengths:
Extensive
literature
search.
Clearly
defined
purpose and
inclusion and
exclusion
criteria.
Reports bias
risk in studies.
PRISMA
provided.
Clear
explanation of
data analysis.
Limitations:
Participants
did not
specifically all
have
hypertension;
had varying
health
conditions.
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Majority (n=62) of
interventions were of
moderate intensity. 13 low
intensity; 11 self-paced, and
5 high intensity.
Walking significantly
reduced SBP and DBP in
both females and males.

Whelton/
2018/ High

To guide health
practitioners with
the best
evidence
regarding the
prevention,
detection
evaluation, and
management of
high BP in
adults.
Guideline

-

-

The use of pedometers
reduces SBP significantly (3.8 mmHg, P < 0.001).
Recommendations for
lifestyle treatment only is for
patients with elevated BP
and patients with stage 1
hypertension who have an
ASCVD risk score <10%.
New definitions:
Normal: SBP <120 and
DBP <80
Elevated: SBP 120-129 and
DBP <80
Stage 1: SBP 130-139 or
DBP 80-89
Stage 2: SBP 140 or DBP
90
Home BP monitoring has
not been shown to reduce
or control BP on its own
without other interventions,
and it is practical for selfmonitoring.

Strengths:
Extensive
literature
search. Clear
grades of
quality and
strength of
evidence.
Removes bias
by including
experts from
various
backgrounds.
Limitations:
None
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Education should be given
to patient about HTN
information, home BP
equipment selection, that
individual BP readings can
vary substantially, and how
to interpret results.
Recommend a structured
PA program to increase PA
in adults who have elevated
BP or HTN.
Aerobic PA: 90-150
min/week 65-75% HR
reserve can lead to a
reduction of 5-8 mmHg in
HTN and 2-4 mmHg in
normotensive adults.
Recommend a target BP of
<130/<80 in adults with
HTN and known CVD or 10year ASCVD risk of 10%.
Suggest that a target BP of
<130/<80 in adults with
HTN without increased CVD
risk may be reasonable.
Cuff size for arm
circumference:
22-26 cm: Small adult
27-34 cm: Adult
35-44 cm: Large adult
45-52: Adult thigh
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Correct HBPM procedures:
-Remain still
-Sit correctly
-Take multiple readings
-Record all readings
accurately
(Further described on page
e25).
Level II Evidence
Baross/2017/
High

To compare how
6 weeks of
different kinds of
training affected
resting SBP,
DBP, and MAP.
Randomized
controlled trial
48 healthy,
sedentary
university
students. 26
were male, 22
were female. All
measures in
female
participants were
taken at the
same point of
their menstrual
cycle.

Randomly allocated to
one of the following
groups for 6 weeks:
a) Simultaneous
walking and isometric
handgrip (WHG)
b) Walking only (WLK)
c) Isometric handgrip
only (IHG)
d) Control (CON)
a) 30 minutes of
treadmill walking at
intensity of 6.5km/hr
4x/week PLUS 10 sec
of isometric handgrip
exercise at 20% of
their MVC, 3x during
the walk (@ 5, 15, &
25 min). Handgrip was
done alternately,
performing twice in
dominant hand.
b) 30 minutes of
treadmill walking at

Resting SBP, DBP, HR

Significant reduction in
resting SBP in WHG group
(127.8 4.5 mmHg to 117.8
3.6 mmHg) versus CON
group (127.9 4.3 mmHg to
127.8 4.3 mmHg)
(P<0.001).
Not significant reduction in
resting SBP in WLK group
(126.7 3.4 mmHg to 122.1
4.2 mmHg) or IHG group
(127.1 4.0 mmHg to 122.2
3.7 mmHg) versus the
CON group (P > 0.05 for
both).
Nonsignificant reductions in
resting DBP versus CON
group (77 1.8 mmHg to
76.5 3.0 mmHg) in:
a) WHG: 77.2 2.8 mmHg
to 73.5 3.8 mmHg

Strengths:
Randomizatio
n; strong
analysis
performed.
Similar
baseline
values
between
groups.
Limitations:
May be
difficult to
generalize
due to sample
characteristics
. No
confidence
intervals
reported.
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Exclusion
criteria: recent (6
months) history
of medical
treatment for
serious illness
(high BP,
orthopedic
injury, viral
illness, or
surgery).
Habitually active.
Participated in
any regular
exercise training
(3 or more
times/week) in
prior 12 months.
Chiang/2019/ To determine the
High
differences in
metabolic
syndrome and
body
composition
under a daily
12,000-step
intervention with
and without
moderateintensity walking
exercises.
Randomized
controlled trial
32 college adults
with obesity.

intensity of 6.5km/hr
4x/week
c) While standing, 10
sec of isometric
handgrip exercise at
20% of their MVC, 3x
(@ 5, 15, & 25 min).
Handgrip was done
alternately, performing
twice in dominant
hand.
All sessions done
under supervision.
d) CON group
continued normal daily
routine.
Randomly assigned to
on one of the following
groups for 8 weeks:
a) Walking step goal
group (WSG; walk
12,000 steps/day), or
b) Walking exercise
group (WEG; 12,000
steps/day PLUS 3
days/week included
walking rate of >103
steps/min for 30
continuous minutes),
or
c) Control group (CG;
daily normal routine)

b) WLK: 77.7 3.0 mmHg to
75.9 2.4 mmHg
c) IHG: 76.3 3.3 mmHg to
73.9 3.9 mmHg

Daily step count and
walking exercises
monitored with a
smartwatch and
exercise log. Resting
SBP, DBP, HR.
Borg Scale of
Perceived Exertion.

SBP in mmHg:
a) WSG: 121.92 to 119.42
b) WEG: 121.36 to 115.09
c) CG: 127.00 to 122.33
DBP in mmHg:
a) WSG: 76.92 to 77.17
b) WEG: 79.55 to 73.45
c) CG: 74.33 to 71.78
Average steps per day:
a) WSG: 11,340.46
b) WEG: 12,288
c) CG: 7,977.74
Mean RPEs for the WEG
group during their 30 minute
walking exercise were

Strengths:
Similar
baseline
characteristics
. Thorough
statistics
performed.
Limitations:
Participants
were between
age 18 and 22
and had no
diabetes or
other chronic
diseases. Not
statistically
significant
changes in
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Gradidge/
2018/
Moderate

Inclusion criteria:
no diabetes or
other chronic
diseases.
Determine the
effect of walking
on obesity. SBP
was secondary
measurement.
Randomized
controlled trial,
parallel, two
group
115 employed
women at a
University in
South Africa;
mean age of
44.4 11.5
years in CG;
mean age of
37.4 8.78 years
in IG

Perl/ 2016/
High

Exclusion:
Pregnant,
illiterate, or
injured
To evaluate if a
structured
educational
program would
decrease BP
and increase
adherence to

significantly higher than pre- SBP and DBP
exercise over 8 weeks
but clinically
(ES=1.85 ~ 2.53, P < 0.05). significant.
Randomly assigned
to:
a) Intervention group
(IG; walk at moderate
intensity (5 to 5.5
km/hr; RPE score of 4
to 8/10) on treadmills
for 30 minutes 3
days/week for 12
weeks while
supervised)
b) Control group (CG;
no treatment)

SBP, DBP, BMI. Sitting
time and moderatevigorous PA (MVPA)
measured using Global
Physical Activity
Questionnaire (GPAQ).

SBP decreased -4.00
mmHg and DBP decreased
-2.40 mmHg in IG. SBP and
DBP increased in the CG
(+5.00 and +5.00 mmHg
respectively).
Increase in MVPA higher in
IG (+193.5 min/week)
versus CG (+25 min/week).
Sitting time of CG increased
by 120 min/day. No change
in sitting time for IG.
No DBP values were
reported.

Crossover design.
Randomly assigned to
two groups:
a) G-I (n=137)
educational program
immediately (T-0)

SBP, DBP at T-6 for
primary endpoint
values.
SBP, DBP at T-12 for
secondary endpoint.

Significantly reduced SBP
in G-I at T-6 from T-0
(P<0.01).
Significant difference in
SBP between G-I and G-II
at T-6 (139 (134-150)

Strengths:
ANCOVA;
feasible
intervention.
Limitations:
Not all data
reported in
Table. Data
that is
reported in
written section
is not what is
shown in the
table. Attrition
bias (12.8%
attrition rate).
The groups
were different
at baseline for
SBP (p=0.17).

Strengths:
Similar
baseline
characteristics
between
groups.
Statistically
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lifestyle
modifications.
Randomized
controlled trial
183 patients
from 13 centers.

b) G-II (n=119)
educational program
at 6 months (T-6)
Follow up visits at T-6
and T-12 (after 12
months).

mmHg vs. 150 (135-165)
mmHg; P < 0.01).

significant
results of
intervention.

DBP reduced, but not
significantly, between the
groups:
T-0: G-I 80 (76-85) mmHg
vs. G-II 84 (75-90) mmHg
T-6: G-I 80 (75-85) mmHg
vs. G-II 80 (76-89) mmHg).

Limitations:
Antihypertensi
ve drugs were
changed
throughout
program, but
researchers
T-12: BP reduction was
did not have
similar between G-I and G-II control over
when both had completed
this.
intervention.
G-I: SBP 134 (128-142)
mmHg; DBP 80 (74-85)
mmHg
G-II: SBP 135 (130-142)
mmHg; DBP 80 (74-86)
mmHg

Note. BMI = body mass index; CVD = cardiovascular disease; DBP = diastolic blood pressure; HBP = high blood pressure; HR =
heart rate; HTN = hypertension; MVC = maximum voluntary contraction; PA = physical activity; RPE = rate of perceived exertion;
SBP = systolic blood pressure; SMBP = self-monitoring of blood pressure; TPE = therapeutic patient education
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APPENDIX G
AGREE II INSTRUMENT
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APPENDIX H
CASP Checklist for Systematic Reviews
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APPENDIX I
CASP Checklist for RCTs
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APPENDIX J
KEY STAKEHOLDER POWERPOINT PRESENTATION
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APPENDIX K
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APPENDIX L
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APPENDIX M
Implementation Calendar
August 2021

September 2021

October 2021

November 2021

August 25: Begin recruitment of participants. Eight-week period begins
as soon as participant is recruited.
Project manager (AYP) will help participant schedule four-week and
eight-week visits.
Education given. Four handouts/log sheets given. AYP measures BP.
AYP fills out demographic form for participant, and AYP will keep for
records/data collection.
September 8: End recruitment of participants. Target numbers
reached.
Between September 23 and October 4: Week four follow-up visit. AYP
will take two BP measurements, five minutes apart, and average them.
Education will be reinforced, and questions will be answered.
Between October 22 and November 4: Week eight follow-up visit.
AYP will take two BP measurements, 5 minutes apart, and average
them. AYP will collect log sheets with data from participants. A
satisfaction survey will be given to complete at this visit.
Final week eight follow-up visits. Develop codebook.

95
APPENDIX N
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APPENDIX O
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APPENDIX P
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APPENDIX Q

ACTION PLAN:
WALKING INTERVENTION FOR HYPERTENSION PATIENTS
Educate on HTN effects.
STEP Discuss BP categories with patient.
1
• Main contributor to heart disease,
stroke, and kidney disease.
• Leading cause of death worldwide.
• Associated with increased risk of
angina, HF, PAD, and AAA.

STEP Recommend structured walking program with goals for minutes per week of moderate2
intensity walking (MIW). Can increase to 150-300 minutes per week for increased
health benefits.

STEP Follow-up via MyChart message: patients send minutes per week of MIW data and BP
3
at one month, two months, six months, and one year.

